Laval, Canada, May 14, 2015/PRNewswire/ — Klox Technologies Inc. (‘Klox’), today announced the formal launch of its lead product, LumiHealTM for the treatment of chronic, acute and surgical wounds along with burns at the annual European Wound Management Association (‘EWMA’) Conference in London, United Kingdom. “We are very excited to bring this pioneering technology to the wound care market – LumiHealTM addresses an unmet need in the market by having bactericidal and healing properties, along with being a single, and easy to use product”, stated Mr. Todd Martensen, Chief Commercial Officer.
At the EWMA Conference, Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies, will be chairing a symposium in regards to Klox’s lead product LumiHealTM with the participation of Dr. Andreas Nikolis, MD, MSc and Dr. Denis Vezina, PhD. “This is an adaptive technology that can really make a difference in the way we manage and treat all types of wounds”, stated Dr. Marco Romanelli. “LumiHealTM represents a significant innovation in a space with limited innovation – we are eager to embrace LumiHealTM within the market”.
In addition to the symposium, Klox will be orally presenting: “Evaluating the effect of BioPhotonic therapy on physical and histologic parameters in an incisional rat model”, and “New technologies in wound care: Klox Technologies” along with a poster presentation of the “Evaluation of the Klox BioPhotonic therapy system on grade II–III pressure sores”.
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on our proprietary BioPhotonic technology platform to address skin and soft tissue disorders. We have a multi-franchise platform focusing on indications across Dermatology, Wound Care, and Oral Health.
The European Wound Management Association (‘EWMA’) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. EWMA is an umbrella organization linking wound management associations across Europe and a multidisciplinary group bringing together individuals and organizations interested in wound management. EWMA works to reach its objectives by being an educational resource, organizing conferences, contributing to international projects related to wound management, actively supporting the implementation of existing knowledge within wound management and providing information on all aspects of wound management.
For more information on Klox, please visit www.kloxtechnologies.com
Mr. Michael Rice – [email protected]
Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Klox Technologies Inc.’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which Klox Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from Klox Technologies Inc.’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.
Source: Original Article